Maze Therapeutics (MAZE) Depreciation & Amortization (CF) (2024 - 2026)
Maze Therapeutics (MAZE) reported Depreciation & Amortization (CF) of $444000.0 for Q1 2026, down 35.09% on a YoY basis from $684000.0 in Q1 2025, and down 10.48% sequentially from $496000.0 in Q4 2025.
Maze Therapeutics (MAZE) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $444000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 35.09% year-over-year to $444000.0; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 28.74% YoY), and the FY2025 full-year result was $2.4 million, down 27.21% from the prior year.
- Depreciation & Amortization (CF) fell to $444000.0 in Q1 2026, from $496000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $950000.0 in Q1 2024 to a low of $444000.0 in Q1 2026.
- A 3-year average of $682333.3 and a median of $684000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) retreated 24.0% in 2025 and slumped 35.09% in 2026, its largest moves.
- Tracing MAZE's Depreciation & Amortization (CF) over 3 years: stood at $705000.0 in 2024, then slipped by 29.65% to $496000.0 in 2025, then dropped by 10.48% to $444000.0 in 2026.
- Business Quant data shows MAZE's Depreciation & Amortization (CF) at $444000.0 in Q1 2026, $496000.0 in Q4 2025, and $571000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | 444,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 444,000.00 |
| Mar 31, 2026 | 444,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Sep 30, 2025 | 571,000.00 |
| Sep 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Mar 31, 2025 | 684,000.00 |
| Mar 31, 2025 | 684,000.00 |
| Dec 31, 2024 | 705,000.00 |
| Dec 31, 2024 | 705,000.00 |
| Sep 30, 2024 | 788,000.00 |
| Sep 30, 2024 | 788,000.00 |
| Jun 30, 2024 | 854,000.00 |
| Jun 30, 2024 | 854,000.00 |
| Mar 31, 2024 | 950,000.00 |
| Mar 31, 2024 | 950,000.00 |